ljc 10627 has been researched along with meropenem in 47 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 18 (38.30) | 18.2507 |
2000's | 15 (31.91) | 29.6817 |
2010's | 9 (19.15) | 24.3611 |
2020's | 5 (10.64) | 2.80 |
Authors | Studies |
---|---|
Jolivette, LJ; Ward, KW | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A | 1 |
Eto, M; Ishii, Y; Mano, Y; Tateda, K; Yamaguchi, K | 1 |
Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R | 1 |
Bell, DT; Culhane, JC; Ebner, DC; Heuer, AM; Ippoliti, JT; Kaushik, A; Lamichhane, G; Parrish, N | 1 |
Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
Ichihara, Y; Mikami, Y; Miyaji, M; Nishimura, C; Ohashi, S; Yazawa, K | 1 |
Bland, S; Dubreuil, L; Grollier, G; Houcke, I; Mory, F; Sedallian, A | 1 |
Hikida, M; Kawashima, K; Mitsuhashi, S; Nishiki, K; Yamazaki, Y; Yoshida, M | 1 |
Day, IP; Goudie, J; Nishiki, K; Williams, PD | 1 |
Andrews, JM; Boswell, FJ; Gill, MJ; Wise, R | 1 |
Bhachech, N; Bush, K; Yang, Y | 1 |
Aldridge, KE; Morice, N; Schiro, DD | 1 |
Chen, HY; Livermore, DM | 1 |
Jones, RN; Sader, HS | 1 |
Hashizume, T; Hazumi, N; Kato, Y; Matsuda, K | 1 |
Kumazawa, J; Matsumoto, T; Nagayama, A | 1 |
Kanazawa, K; Nouda, H; Sunagawa, M | 1 |
Hirata, Y; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kawaguchi, R; Kobayashi, I; Kumasaka, K; Matsuoka, K; Murakami, E; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Okamoto, E; Saeki, H; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uchida, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
Horii, T; Ichiyama, S; Kobayashi, M; Ohta, M | 1 |
Hirata, Y; Hongo, T; Igari, J; Imafuku, Y; Inoue, M; Kawaguchi, R; Kobayashi, I; Kobayasi, Y; Kumasaka, K; Matsumoto, N; Nakasaki, N; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Saeki, H; Sasaki, T; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
Murase, M | 1 |
Fujimura, S; Gomi, K; Honda, Y; Kikuchi, T; Kobayashi, T; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A; Yasui, S | 1 |
Aoki, N; Hashimoto, T; Hirata, Y; Hongo, T; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kajimura, K; Kawaguchi, R; Kobayashi, I; Kobayashi, Y; Kumasaka, K; Matsumoto, N; Matsuoka, K; Murakami, E; Nakasaki, N; Nishino, T; Oguri, T; Ohba, Y; Ohtaki, Y; Okada, J; Okamoto, E; Ono, J; Saeki, H; Sasaki, T; Satou, S; Shibano, T; Takahashi, A; Takata, T; Tokuda, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
Endo, H; Jinbo, K; Nishinari, C; Suzuki, Y; Tamura, C | 1 |
Hikida, M; Inoue, M; Okamoato, R; Sato, Y; Terashima, S | 1 |
Araake, M; Gotoh, N; Hiraishi, T; Miyata, A; Nishino, T; Ogawa, H; Takata, T | 1 |
Araake, M; Hara, T; Watabe, H | 1 |
Inoue, M; Kaku, M; Nasu, M; Sagawa, K; Yokoyama, T | 1 |
Aizawa, K; Sakakibara, S; Shimizu, A; Takata, T; Totsuka, K; Watabe, H | 1 |
Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
Kobayashi, Y; Sumitani, Y | 1 |
Mikamo, H; Tanaka, K; Watanabe, K; Yamagishi, Y | 1 |
Derendorf, H; Ikawa, K; Ikeda, K; Morikawa, N; Murakami, Y; Nakashima, A; Ohge, H; Sueda, T | 1 |
Araki, N; Harada, Y; Hasegawa, H; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Yamada, K; Yamamoto, Y; Yanagihara, K | 1 |
Ding, G; Hao, Q; Hu, C; Liu, H; Lv, X; Qin, Z; Tong, C; Wang, X; Xin, J; Xiong, Y; Yu, R; Zhang, X; Zong, Z | 1 |
Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U | 1 |
Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
Bell, DT; Chauhan, V; Kaushik, A; Kumar, P; Lamichhane, G; Stevens, RL; Xia, F | 1 |
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y | 1 |
Akao, T; Ichimura, Y; Kudoh, N; Murabe, T; Oda, M; Saito, T; Saitoh, H; Suzuki, T; Watanuki, S | 1 |
Tiwaskar, M; Vora, A | 1 |
George Priya Doss, C; Gopikrishnan, M | 1 |
1 review(s) available for ljc 10627 and meropenem
Article | Year |
---|---|
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
1 trial(s) available for ljc 10627 and meropenem
Article | Year |
---|---|
Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.
Topics: Adult; Aged; Bacteria; Bacterial Infections; China; Female; Humans; Infusions, Intravenous; Male; Meropenem; Middle Aged; Respiratory Tract Infections; Thienamycins; Urinary Tract Infections | 2013 |
45 other study(ies) available for ljc 10627 and meropenem
Article | Year |
---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship | 2009 |
In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa | 2010 |
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship | 2015 |
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Structure-Activity Relationship | 2016 |
In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
Topics: Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Nocardia; Thienamycins | 1992 |
[In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria].
Topics: Bacteroides fragilis; Clostridium; Dose-Response Relationship, Drug; Eubacterium; Fusobacterium; Humans; Imipenem; In Vitro Techniques; Meropenem; Peptostreptococcus; Prevotella; Thienamycins | 1995 |
Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
Topics: Animals; Ceftazidime; Cephalosporins; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1995 |
Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
Topics: Analysis of Variance; Animals; Binding, Competitive; Cilastatin; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Imipenem; Injections, Intravenous; Male; Meropenem; Mice; Muscimol; Pentylenetetrazole; Rats; Receptors, GABA-A; Seizures; Thienamycins | 1995 |
Postantibiotic effects of three carbapenems on Pseudomonas aeruginosa in the presence of lysine.
Topics: Carbapenems; Imipenem; Lysine; Meropenem; Pseudomonas aeruginosa; Thienamycins | 1995 |
Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
Topics: Bacteria; Bacterial Proteins; beta-Lactamases; Carrier Proteins; Cell Membrane Permeability; Hexosyltransferases; Hydrolysis; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Thienamycins | 1995 |
In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
Topics: Bacteria, Anaerobic; beta-Lactamases; Drug Resistance, Microbial; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1994 |
In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbenicillin; Enzyme Induction; Hydrolysis; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillin Resistance; Porins; Pseudomonas aeruginosa; Thienamycins | 1994 |
Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
Topics: Anti-Bacterial Agents; Bacteremia; Bacteria; Ceftazidime; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1993 |
Effects of a beta-lactamase inhibitor, sulbactam, on the activity of carbapenems against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Pseudomonas aeruginosa; Sulbactam; Thienamycins | 1995 |
Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins; Urinary Tract Infections | 1996 |
Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins. Effect of 1 beta-methyl group and C-2 side chain.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Carrier Proteins; Haemophilus influenzae; Hexosyltransferases; Imipenem; Meropenem; Methylation; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Structure-Activity Relationship; Thienamycins | 1997 |
[Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: 4-Quinolones; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Pseudomonas aeruginosa; Serratia marcescens; Thienamycins | 1997 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa.
Topics: Carbapenems; Endotoxins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins; Time Factors | 1999 |
[In vitro antibacterial activities of carbapenems against clinical isolates].
Topics: Bacteria; Enterobacteriaceae; Imipenem; Meropenem; Methicillin Resistance; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 1999 |
[In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Topics: Bacteria; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Penicillins; Piperacillin; Respiratory Tract Infections; Thienamycins; Time Factors | 1999 |
[Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents].
Topics: Bacteria; Carbapenems; Drug Resistance, Microbial; Humans; Imipenem; Japan; Meropenem; Multicenter Studies as Topic; Thienamycins; Time Factors | 2000 |
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
Topics: Bacteria; Carbapenems; Cefepime; Cefozopran; Cephalosporins; Imipenem; Meropenem; Thienamycins | 2001 |
[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2001 |
[Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Imipenem; Meropenem; Mutation; Pseudomonas aeruginosa; Thienamycins | 2002 |
[Antibacterial activity of biapenem against recent clinical isolates].
Topics: Bacteria; Bacterial Infections; beta-Alanine; Carbapenems; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Thienamycins | 2003 |
[Proper use of carbapenem antibiotics based on the feature in the treatment of infectious diseases (discussion)]].
Topics: Bacteria; Bacterial Infections; beta-Alanine; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Thienamycins; Treatment Failure | 2004 |
Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Drug Administration Schedule; Humans; Imipenem; Male; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Thigh | 2004 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Meropenem; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2007 |
[Clinical investigation on target value of T>MIC in carbapenems].
Topics: Adult; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Drug Administration Schedule; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Meropenem; Middle Aged; Pelvic Inflammatory Disease; Staphylococcus aureus; Thienamycins | 2008 |
Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bile; Biliary Tract; Dose-Response Relationship, Drug; Drug Administration Schedule; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2011 |
In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Case-Control Studies; Colony Count, Microbial; Disease Models, Animal; Histocytochemistry; Lung; Male; Meropenem; Mice; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Specific Pathogen-Free Organisms; Statistics, Nonparametric; Thienamycins | 2012 |
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Doripenem; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Rifampin; Thienamycins | 2015 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; Cephalosporins; Clavulanic Acid; DNA, Intergenic; Gene Expression; Genetic Loci; Humans; Meropenem; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Protein Binding; Thienamycins; Tuberculosis, Multidrug-Resistant | 2017 |
In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ambroxol; Amlodipine; Anti-Bacterial Agents; Carbapenems; Cefoperazone; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2020 |
Inhibitory effects of indoxyl sulfate and creatinine on the renal transport of meropenem and biapenem in rats.
Topics: Animals; Creatinine; Humans; Indican; Kidney; Meropenem; Organic Anion Transporters, Sodium-Independent; Rats; Thienamycins; Uremic Toxins | 2021 |
Biapenem.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2022 |
Molecular docking and dynamic approach to screen the drug candidate against the Imipenem-resistant CarO porin in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Porins | 2023 |